Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 27, 2026.

Sign in

Processa Pharmaceuticals, Inc.

PCSA Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Add to portfolio Download report
Today
1.4%
Previous close
$1.80
Market cap
$5.0M
P/E
1.8x
Day range
$1.71 $1.87
52-week range
$1.35 $9.73

Last close Β· Oct 27, 2026

$1.82

βˆ’$5.96 (βˆ’76.59%) past year

Share price

Processa Pharmaceuticals, Inc.

What Processa Pharmaceuticals, Inc. does

PCSA Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
Processa Pharmaceuticals, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 18, 2026
Accession Β· CIK
0001493152-26-011204 Β· 0001533743

Earnings calendar Β· Processa Pharmaceuticals, Inc.

Every quarter, companies publish how much they sold and earned. These are the days Processa Pharmaceuticals, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 5, 2026

Thursday Β· in 9 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 14, 2026 Q2 '26 After the market closes 10-Q β†—
May 7, 2026 Q1 '26 After the market closes 10-Q β†—
Mar 18, 2026 Q4 '25 After the market closes 10-K β†—
Nov 6, 2025 Q3 '25 After the market closes 10-Q β†—
Aug 7, 2025 Q2 '25 Before the market opens 10-Q β†—
May 8, 2025 Q1 '25 After the market closes 10-Q β†—
Mar 20, 2025 Q4 '24 After the market closes 10-K β†—
Oct 30, 2024 Q3 '24 After the market closes 10-Q β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Processa Pharmaceuticals, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

1 to watch

Processa Pharmaceuticals, Inc. in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$13.6M

No. It lost money last year.

For information

How is the share priced?

1.8x

One share costs 1.8 times its yearly profit per share.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$5.0M
Oct 27 close
P/E Last close divided by diluted earnings per share over the last four quarters.
1.8x
On $1.00 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Processa Pharmaceuticals, Inc. lost $13.6M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Net income and earnings per share

Loss periods are shown in red.

KIRA summarises the numbers

  • Processa Pharmaceuticals, Inc. lost $13.6M in fiscal 2025.

Net income

Net income

Diluted EPS

Diluted EPS

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

Cash from operations minus capital spending.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Dividends, buybacks and share count

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

KIRA summarises the numbers

  • In the last 12 months, insiders bought $0.2M of shares on the open market and sold none.

Bought, 12 months

$0.2M

9 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

DateInsiderTradeSharesPriceValueFiling
Jul 1, 2026 George K NgChief Executive Officer, Director Bought 3,057 $1.93 $0.0M Form 4
Jun 30, 2026 Wendy GuyChief Administrative Officer Bought 2,436 $1.93 $0.0M Form 4
Jun 30, 2026 Patrick LinChief Business - Strategy Off Bought 2,106 $1.93 $0.0M Form 4
Jun 30, 2026 David YoungPres. Research & Development, Director Bought 2,531 $1.93 $0.0M Form 4
Jun 30, 2026 Russell SkibstedChief Financial Officer Bought 3,277 $1.93 $0.0M Form 4
Jun 15, 2026 Russell SkibstedChief Financial Officer Bought 2,654 $2.22 $0.0M Form 4
Jun 15, 2026 Patrick LinChief Business - Strategy Off Bought 1,831 $2.22 $0.0M Form 4
Jun 15, 2026 George K NgChief Executive Officer, Director Bought 2,465 $2.22 $0.0M Form 4
Jun 15, 2026 David YoungPres. Research & Development, Director Bought 2,067 $2.22 $0.0M Form 4
Jun 15, 2026 Wendy GuyChief Administrative Officer Bought 2,118 $2.22 $0.0M Form 4
May 29, 2026 Russell SkibstedChief Financial Officer Bought 2,292 $2.57 $0.0M Form 4
May 29, 2026 George K NgChief Executive Officer, Director Bought 2,129 $2.57 $0.0M Form 4
May 29, 2026 David YoungPres. Research & Development, Director Bought 1,786 $2.57 $0.0M Form 4
May 29, 2026 Wendy GuyChief Administrative Officer Bought 1,829 $2.57 $0.0M Form 4
May 29, 2026 Patrick LinChief Business - Strategy Off Bought 1,582 $2.57 $0.0M Form 4
May 15, 2026 Wendy GuyChief Administrative Officer Bought 1,583 $2.97 $0.0M Form 4
May 15, 2026 Patrick LinChief Business - Strategy Off Bought 1,369 $2.97 $0.0M Form 4
May 15, 2026 Russell SkibstedChief Financial Officer Bought 1,984 $2.97 $0.0M Form 4
May 15, 2026 David YoungPres. Research & Development, Director Bought 1,545 $2.97 $0.0M Form 4
May 15, 2026 George K NgChief Executive Officer, Director Bought 1,843 $2.97 $0.0M Form 4
Apr 30, 2026 Patrick LinChief Business - Strategy Off Bought 1,511 $2.69 $0.0M Form 4
Apr 30, 2026 David YoungPres. Research & Development, Director Bought 1,706 $2.69 $0.0M Form 4
Apr 30, 2026 Wendy GuyChief Administrative Officer Bought 1,748 $2.69 $0.0M Form 4
Apr 30, 2026 Sian BigoraChief Development Officer Bought 1,986 $2.69 $0.0M Form 4
Apr 30, 2026 George K NgChief Executive Officer, Director Bought 2,034 $2.69 $0.0M Form 4
Apr 30, 2026 Russell SkibstedChief Financial Officer Bought 2,190 $2.69 $0.0M Form 4
Apr 15, 2026 Russell SkibstedChief Financial Officer Bought 1,984 $2.97 $0.0M Form 4
Apr 15, 2026 George K NgChief Executive Officer, Director Bought 1,843 $2.97 $0.0M Form 4
Apr 15, 2026 Sian BigoraChief Development Officer Bought 1,799 $2.97 $0.0M Form 4
Apr 15, 2026 Wendy GuyChief Administrative Officer Bought 1,583 $2.97 $0.0M Form 4
Apr 15, 2026 Patrick LinChief Business - Strategy Off Bought 1,369 $2.97 $0.0M Form 4
Apr 15, 2026 David YoungPres. Research & Development, Director Bought 1,545 $2.97 $0.0M Form 4
Mar 31, 2026 Geraldine PannuDirector Bought 2,072 $2.54 $0.0M Form 4
Mar 31, 2026 Russell SkibstedChief Financial Officer Bought 2,324 $2.54 $0.0M Form 4
Mar 31, 2026 James R NealDirector Bought 789 $2.54 $0.0M Form 4
Mar 31, 2026 Sian BigoraChief Development Officer Bought 2,107 $2.54 $0.0M Form 4
Mar 31, 2026 Khoso BaluchDirector Bought 2,269 $2.54 $0.0M Form 4
Mar 31, 2026 Wendy GuyChief Administrative Officer Bought 1,854 $2.54 $0.0M Form 4
Mar 31, 2026 Patrick LinChief Business - Strategy Off Bought 1,603 $2.54 $0.0M Form 4
Mar 31, 2026 George K NgChief Executive Officer, Director Bought 2,136 $2.54 $0.0M Form 4
Mar 31, 2026 David YoungPres. Research & Development, Director Bought 1,810 $2.54 $0.0M Form 4

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Processa Pharmaceuticals, Inc. can carry it.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $16.5M$6.5M$4.7M$1.2M$5.5M
Interest coverage βˆ’30,333.8xβ€”β€”β€”β€”
Current ratio 18.9x8.4x7.7x1.2x2.5x
Quick ratio 18.9x8.4x7.7x1.2x2.5x
Total assets $26.5M$8.6M$5.8M$3.2M$7.8M
Total liabilities $1.0M$1.1M$0.8M$1.5M$2.2M
Shareholders' equity $25.5M$7.5M$5.0M$1.7M$5.6M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”β€”

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ“ βœ“ βœ• βœ• βœ“ βœ• βœ“ βœ• βœ“
Cash from operations exceeds net income βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” βœ“ β€” β€” β€” β€” β€” β€” β€”
Current ratio rose β€” βœ• βœ“ βœ• βœ“ βœ“ βœ• βœ• βœ• βœ“
Share count didn't rise β€” βœ• βœ“ βœ• βœ• βœ• βœ“ βœ• βœ“ βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” β€” β€” β€” β€” βœ• β€” β€” β€”
F-score β€” / 3β€” / 65 / 7β€” / 6β€” / 6β€” / 62 / 7β€” / 6β€” / 6β€” / 6
Accruals ratio 10.1%βˆ’7.5%βˆ’0.7%βˆ’5.2%βˆ’62.4%βˆ’10.5%βˆ’101.6%βˆ’42.5%βˆ’13.4%βˆ’39.5%
Altman Z'' βˆ’26.38βˆ’7.35βˆ’0.04βˆ’2.907.1724.04βˆ’33.31βˆ’43.64βˆ’111.26βˆ’48.58

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $0.0M β€” β€” β€” β€” $0.0M $0.0M β€” β€” β€”
Gross profit $0.0M β€” β€” β€” β€” β€” β€” β€” β€” β€”
Research and development $1.5M $1.0M $3.1M $2.3M $3.2M $6.9M $11.5M $5.8M $7.3M $7.8M
Operating income βˆ’$1.9M βˆ’$1.8M βˆ’$4.5M βˆ’$3.9M βˆ’$15.1M βˆ’$12.1M βˆ’$27.5M βˆ’$11.5M βˆ’$12.1M βˆ’$14.0M
Interest expense $0.2M $0.1M $0.2M $0.0M $0.3M $0.0M β€” β€” β€” β€”
Pretax income βˆ’$0.3M βˆ’$1.9M βˆ’$4.7M βˆ’$4.0M βˆ’$15.4M βˆ’$12.0M βˆ’$27.4M βˆ’$11.1M βˆ’$11.9M βˆ’$13.6M
Income tax β€” $0.3M βˆ’$0.9M βˆ’$0.6M βˆ’$1.0M βˆ’$0.5M β€” β€” β€” β€”
Net income βˆ’$1.9M βˆ’$1.9M βˆ’$3.8M βˆ’$3.4M βˆ’$14.4M βˆ’$11.4M βˆ’$27.4M βˆ’$11.1M βˆ’$11.9M βˆ’$13.6M
Net income to common βˆ’$0.4M β€” βˆ’$3.8M βˆ’$3.9M βˆ’$19.0M βˆ’$11.4M βˆ’$27.4M βˆ’$11.1M βˆ’$11.9M βˆ’$13.6M
Diluted EPS βˆ’$0.07 βˆ’$0.06 βˆ’$0.71 βˆ’$0.70 βˆ’$2.54 βˆ’$0.75 βˆ’$34.05 βˆ’$8.48 βˆ’$96.78 βˆ’$10.36
Diluted shares 0.03B 0.03B 0.01B 0.01B 0.01B 0.02B 0.00B 0.00B 0.00B 0.00B
Cash flow
Cash from operations βˆ’$2.2M βˆ’$1.7M βˆ’$3.7M βˆ’$2.8M βˆ’$3.1M βˆ’$8.7M βˆ’$9.6M βˆ’$8.1M βˆ’$11.2M βˆ’$11.4M
Capital expenditure $0.0M $0.0M β€” β€” β€” β€” β€” $0.0M $0.0M β€”
Free cash flow βˆ’$2.2M βˆ’$1.7M β€” β€” β€” β€” β€” βˆ’$8.1M βˆ’$11.2M β€”
Depreciation and amortization $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M β€” $0.0M $0.0M $0.0M
Stock-based compensation $0.0M β€” $0.1M $0.5M $2.7M $3.4M $8.8M $1.1M $0.6M $0.9M
Balance sheet
Cash and short-term investments $1.1M $2.8M $1.7M $0.7M $15.4M $16.5M $6.5M $4.7M $1.2M $5.5M
Total debt β€” $2.4M $0.2M β€” β€” β€” β€” β€” β€” β€”
Finance lease liabilities β€” β€” β€” β€” β€” β€” β€” β€” $0.0M β€”
Current assets $2.3M $3.0M $2.0M $1.0M $16.2M $18.3M $8.4M $5.6M $1.9M $5.7M
Current liabilities $0.1M $2.6M $0.6M $1.2M $1.2M $1.0M $1.0M $0.7M $1.5M $2.2M
Property and equipment, net $0.0M $0.0M $0.0M $0.0M $0.0M β€” β€” $0.0M $0.0M $0.0M
Intangible assets β€” β€” $10.4M $9.6M $8.8M $8.1M β€” β€” β€” β€”
Total assets $2.4M $3.0M $12.5M $10.9M $25.2M $26.5M $8.6M $5.8M $3.2M $7.8M
Total liabilities $0.1M $2.6M $2.8M $2.9M $2.3M $1.0M $1.1M $0.8M $1.5M $2.2M
Preferred stock $0.0M β€” β€” β€” β€” β€” β€” β€” β€” β€”
Shareholders' equity βˆ’$2.3M $0.4M $9.7M $8.0M $22.9M $25.5M $7.5M $5.0M $1.7M $5.6M
Margins
Gross margin 100.0% β€” β€” β€” β€” β€” β€” β€” β€” β€”
Operating margin βˆ’38,430.0% β€” β€” β€” β€” β€” β€” β€” β€” β€”
EBITDA margin βˆ’38,402.0% β€” β€” β€” β€” β€” β€” β€” β€” β€”
Net margin βˆ’38,342.0% β€” β€” β€” β€” β€” β€” β€” β€” β€”
FCF margin βˆ’43,576.0% β€” β€” β€” β€” β€” β€” β€” β€” β€”
Returns
Return on capital β€” β€” βˆ’43.6% β€” β€” β€” β€” β€” β€” β€”
Return on capital employed βˆ’84.8% βˆ’470.5% βˆ’38.2% βˆ’40.6% βˆ’63.1% βˆ’47.6% βˆ’361.2% βˆ’226.6% βˆ’710.3% βˆ’250.8%
Return on equity β€” β€” βˆ’74.7% βˆ’37.9% βˆ’93.1% βˆ’47.2% βˆ’166.4% βˆ’178.5% βˆ’354.5% βˆ’373.0%
Return on assets βˆ’81.1% βˆ’69.4% βˆ’48.7% βˆ’28.7% βˆ’79.9% βˆ’44.2% βˆ’156.3% βˆ’154.4% βˆ’262.9% βˆ’245.7%
Return on tangible equity β€” βˆ’497.4% β€” β€” βˆ’135.1% βˆ’65.6% βˆ’367.1% βˆ’222.9% βˆ’698.6% βˆ’243.2%
Growth
Share count change β€” 11.2% βˆ’83.6% 3.6% 35.7% 104.3% βˆ’94.7% 62.8% βˆ’90.7% 969.7%
Financial health
Debt / equity β€” 6.6x 0.0x β€” β€” β€” β€” β€” β€” β€”
Interest coverage βˆ’7.8x βˆ’30.5x βˆ’28.1x βˆ’107.2x βˆ’53.8x βˆ’30,333.8x β€” β€” β€” β€”
Current ratio 23.9x 1.1x 3.1x 0.8x 13.3x 18.9x 8.4x 7.7x 1.2x 2.5x
Quick ratio 23.9x 1.1x 3.1x 0.8x 13.3x 18.9x 8.4x 7.7x 1.2x 2.5x
Capital allocation
Capex / revenue 476.0% β€” β€” β€” β€” β€” β€” β€” β€” β€”
Stock comp / revenue 134.0% β€” β€” β€” β€” β€” β€” β€” β€” β€”
Quality scores
Piotroski F-score β€” β€” 5.0 β€” β€” β€” 2.0 β€” β€” β€”
Altman Z'' βˆ’26.4 βˆ’7.4 βˆ’0.0 βˆ’2.9 7.2 24.0 βˆ’33.3 βˆ’43.6 βˆ’111.3 βˆ’48.6
Accruals ratio 10.1% βˆ’7.5% βˆ’0.7% βˆ’5.2% βˆ’62.4% βˆ’10.5% βˆ’101.6% βˆ’42.5% βˆ’13.4% βˆ’39.5%

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Source: SEC EDGAR XBRL filings (CIK 0001533743). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open